• The document contains the transcript of an Earnings Call held on Friday, July 31, 2026, for the first quarter ended June 30, 2026 (Q1 FY27).
  • The event was a post-results investor interaction conference call to discuss Q1 FY27 financial performance and business updates.
  • Management participants included Dr. Yasir Rawjee (Managing Director and Chief Executive Officer), Mr. Tushar Mistry (Chief Financial Officer), and Ms. Soumi Rao (Senior General Manager).
  • The company stated that the recording and transcript of the call would be available on the company's website at https://alivus.b-cdn.net/alivuspdfs/investors/financials/reports_presentation/Alivus-Earnings-Jul31-2026.pdf.
  • The opening remarks included standard forward-looking statement disclaimers, noting that information shared may contain forward-looking statements involving risks and uncertainties, and the company undertakes no obligation to update or revise such statements.

Financial Highlights Discussed:

  • Revenue from operations: INR640 crores, representing 6.4% year-on-year growth
  • Gross profit: INR385 crores, up 16.3% year-on-year
  • Gross margins: 60.2%, increased 510 basis points year-on-year
  • EBITDA: INR234 crores, up 29.1% year-on-year
  • EBITDA margin: 36.6%, increased 650 basis points year-on-year
  • PAT: INR160 crores with PAT margins at 25%
  • Non-GPL business growth: 26.5% year-on-year
  • GPL business decline: 52.6% year-on-year
  • CDMO business growth: 3.8% year-on-year
  • R&D expenditure: INR24 crores (3.7% of sales)
  • Capex for the quarter: INR85 crores
  • FY27 capex guidance: Approximately INR540 crores
  • Cash and cash equivalents including short-term investments: INR880 crores as of June 30, 2026
  • Company remains debt-free

Business Performance Details:

  • Therapeutic mix: CVS and CNS contributed 58% to top line; chronic therapies accounted for 74% of top line
  • Pipeline status: 617 DMF and CEP filings globally as of June 30, 2026
  • High-potent API portfolio: 29 products in active grid representing total addressable market of $82 billion (13 validated, 7 in advanced development, 9 in lab development)

Guidance and Outlook:

  • FY27 revenue growth guidance: 10% to 12% with growth skewed towards H2 FY27
  • EBITDA margin guidance: 30% to 32% range (management indicated potential for up to 34% if geopolitical situation improves)
  • GPL business expected to remain flattish in FY27 with stronger H2 performance
  • Non-GPL business expected to maintain healthy growth momentum
  • CDMO segment expected to gain momentum in second half of the year

Capacity Expansion Updates:

  • Solapur facility expected to be operational in early Q3 FY27 (slight delay)
  • Taloja R&D center construction begun and on schedule
  • Brownfield expansion ongoing at Ankleshwar and Dahej facilities

Additional Notes Section

  • The document includes the full transcript of the earnings call Q&A session with analysts from Unifi Capital, Omega Portfolio Advisors, Paul Asset, Eyesight Fintrade Private Limited, Unique PMS, and Ambit Asset Management.
  • The transcript was attached to the regulatory filing submitted to BSE Ltd. and National Stock Exchange of India Ltd.
  • The company included standard compliance language regarding forward-looking statements but did not explicitly state that no unpublished price sensitive information (UPSI) would be shared.
  • No financial data beyond what was already disclosed in the results was shared during the call.